Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

COVID-19 can cause skin issues like rashes and hair loss, which may last even after recovery.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

Men generally face more severe COVID-19 outcomes than women, partly due to hormonal differences.

Public interest in skin issues changed during COVID-19, with more focus on dry skin, hair problems, and hand eczema.

Sex hormones may influence COVID-19 severity, with males at higher risk, and certain hormone therapies could potentially treat the virus.

Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.

Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.

Frankincense may help treat COVID-19, but more research is needed.

Females have stronger immune responses to COVID-19 than males, leading to better outcomes.

Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.

Hydroxychloroquine and chloroquine are not recommended for COVID-19 treatment due to insufficient evidence and safety concerns.

Gender and social factors, not just biology, affect COVID-19 death rates.

Interest in long-COVID symptoms in Japan increased with COVID-19 case peaks, especially for hair loss, cough, smell/taste issues, and headache.

Reprogramming macrophages to resolve inflammation can help reduce severe COVID-19 complications.

A standardized drug development platform is essential for efficient and effective drug repurposing, especially during pandemics.

More skin issues appeared in the emergency department during COVID-19, highlighting the need for better dermatology training and resources.

Pulmonary delivery of cepharanthine significantly improves its effectiveness and shows promise for treating lung fibrosis linked to COVID-19.

Drug repositioning offers a cost-effective, lower-risk way to treat diseases and pandemics like COVID-19.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

COVID-19 may cause temporary hair loss due to direct damage to hair follicles, but it usually gets better on its own.

Mice with a virus similar to COVID-19 had skin damage, but a special treatment helped repair it.

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

Long COVID can cause anemia and iron issues, leading to fatigue and slow recovery, especially in men and severe cases.

Multimedia education greatly improves women's knowledge and management of PCOS.

Women, younger age, and low BMI increase the risk of long COVID symptoms.

More research is needed to understand sex and racial differences in long COVID.

COVID-19 may cause hair loss by affecting hair follicles.

COVID-19 vaccination may lower vitamin D levels and cause hair loss.

Metformin may help mild COVID-19 cases, while Oseltamivir, Tamoxifen, and Dexamethasone are suggested for severe cases.

Spironolactone may help reduce COVID-19 severity in men by blocking harmful effects of certain hormones.